Environmental exposure to polycyclic aromatic hydrocarbons (PAHs) has been associated with cardiovascular disease, yet the specific metabolites and cell-type-resolved mechanisms underlying stroke risk remain poorly defined. Here, we applied an integrated multilevel framework combining population-based exposure analysis with network toxicology, transcriptomics, and single-cell validation to investigate how PAH exposure, using 2-naphthol (2-NAP) as a representative metabolite, may contribute to stroke. PAH metabolites were analyzed in relation to stroke using logistic regression and restricted cubic splines, while mixture effects were evaluated using weighted quantile sum regression and machine-learning models. Network toxicology combined with transcriptomic and machine-learning analyses was used to identify candidate genes and prioritize four putative core genes (DPP4, IFIH1, KAT6A, and LAMP2). Single-cell RNA sequencing further resolved the cell-type-specific expression of these genes, highlighting endothelial cell and macrophage subsets and implicating TGF-β-related signaling pathways. Molecular docking suggested a direct interaction between the key metabolite 2-NAP and LAMP2, which was further examined in vitro. Functional experiments demonstrated that 2-NAP exposure increased LAMP2 expression, induced endothelial DNA damage, impaired microglial migration, and enhanced the production of pro-inflammatory cytokines. Together, these findings suggest that 2-NAP may represent an important contributor linking PAH exposure to stroke and that LAMP2-associated pathways may participate in PAH-related cerebrovascular injury. This study provides mechanistic insight by bridging epidemiological associations with defined molecular pathways and cerebrovascular cell populations, strengthening the biological plausibility of PAH-related stroke risk.
Jian Cui, Wen-Jie Xu, Jia-Rong He et al.· Ecotoxicology and Environmen...· 0 citations
Alzheimer's disease (AD) is the most dominant form of dementia characterized by neurodegeneration which leads to progressive cognitive decline and memory loss, the common symptoms of AD. While amyloid-β peptide accumulation has traditionally been the primary focus of AD research, there is growing evidence that tau pathology also contributes significantly in disease progression. Tau is a microtubule-associated protein that normally stabilizes microtubules and supports axonal transport within neurons. However, abnormal hyperphosphorylation causes tau to detach from microtubules, misfold and aggregate into toxic filaments which ultimately lead to neurodegeneration and eventually cell death. This paper reviews the structure of tau protein, its physiological and pathological behaviours and tau's mechanism in terms of disease progression. This paper also examines clinical and preclinical evidences and discusses the efficacy and limitations of three tau-targeted therapeutic approaches: gosuranemab, a monoclonal antibody designed to prevent the spread of extracellular tau; BIIB080, an antisense oligonucleotide that reduces tau production by targeting MAPT mRNA; and leucomethylthioninium bis (LMTM), a tau aggregation inhibitor. Studies also suggest the potential of combination therapies targeting multiple pathological pathways to enhance efficacy. Though no tau-targeted therapy has yet to demonstrate definitive clinical benefit, continued research supports tau as an important therapeutic target and contributes to the development of more effective treatments for AD.
Zhuo-Yu Wang· MedScien· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.